...
首页> 外文期刊>Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease >Dipeptidyl Peptidase-4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow-Mediated Vasodilatation in Type 2 Diabetic Patients
【24h】

Dipeptidyl Peptidase-4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow-Mediated Vasodilatation in Type 2 Diabetic Patients

机译:通过流介导的血管舒张术评估2型糖尿病患者的二肽基肽酶4抑制剂减弱内皮功能。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Endothelial dysfunction is an independent predictor for cardiovascular events in patients with type 2 diabetes (T2DM). Glucagon like peptide-1 (GLP-1) reportedly exerts vasodilatory actions, and inhibitors of dipeptidyl peptidase-4 (DPP-4), an enzyme-degrading GLP-1, are widely used to treat T2DM. We therefore hypothesized that DPP-4 inhibitors (DPP-4Is) improve endothelial function in T2DM patients and performed 2 prospective, randomized crossover trials to compare the DPP-4I sitagliptin and an α-glucosidase inhibitor, voglibose (in study 1) and the DPP-4Is sitagliptin and alogliptin (in study 2).
机译:背景内皮功能障碍是2型糖尿病(T2DM)患者心血管事件的独立预测因子。据报道,胰高血糖素样肽1(GLP-1)发挥血管舒张作用,并且降解酶的GLP-1二肽基肽酶4(DPP-4)抑制剂被广泛用于治疗T2DM。因此,我们假设DPP-4抑制剂(DPP-4Is)改善了T2DM患者的内皮功能,并进行了2项前瞻性,随机交叉试验,以比较DPP-4I西他列汀和α-葡萄糖苷酶抑制剂伏格列波糖(研究1)和DPP -4是西他列汀和阿格列汀(在研究2中)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号